DCP
NBIX icon

Distillate Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Distillate Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Sell
92,592
-669
-0.7% -$99.3K 0.81% 71
2026
Q1 		$12.3M Buy
93,261
+722
+0.8% +$95.8K 0.65% 90
2025
Q4 		$13.1M Sell
92,539
-1,877
-2% -$272K 0.68% 89
2025
Q3 		$13.3M Sell
94,416
-27,198
-22% -$3.69M 0.69% 86
2025
Q2 		$15.3M Sell
121,614
-8,175
-6% -$938K 0.82% 58
2025
Q1 		$14.4M Buy
+129,789
New +$16.4M 0.74% 69

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Distillate Capital Partners's NBIX Position: Q2 2026 in Review

Distillate Capital Partners reduced its Neurocrine Biosciences (NBIX) stake by 0.72% in Q2 2026, selling an estimated $99.3K and leaving 92,592 shares worth $15.6M. The position accounts for 0.81% of the portfolio, ranked #71.

Distillate Capital Partners first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Distillate Capital Partners held 92,592 shares of Neurocrine Biosciences worth $15.6M as of Q2 2026.
  • Distillate Capital Partners sold 669 Neurocrine Biosciences shares in Q2 2026, an estimated $99.3K.
  • Neurocrine Biosciences made up 0.81% of Distillate Capital Partners's portfolio in Q2 2026, its #71 holding.
  • Distillate Capital Partners first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Distillate Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.